• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Characterisation and virus safety of alpha 1-proteinase inhibitor.

作者信息

Coan M H, Dobkin M B, Brockway W J, Mitra G

机构信息

Research Division, Cutter Biological of Miles Inc., Berkeley, California.

出版信息

Eur Respir J Suppl. 1990 Mar;9:35s-38s.

PMID:2340049
Abstract

Alpha 1-proteinase inhibitor (alpha 1-PI) concentrate is prepared from Cohn fraction IV-1 by precipitation and ion-exchange chromatography. A pasteurisation step (60 degrees, 10 hours) is introduced in this process with the aim at lowering the risk of transmitting infectious agents. Characterisation studies of alpha 1-PI with electrophoretic, immunologic and chemical methods demonstrated that the final product behaved the same as alpha 1-PI in human plasma. In particular, neo-antigens were not detected and the association rate constant of the final product was shown to be very similar to the constant published in the literature. The inactivation kinetic studies of eight different viruses showed that the heat treatment had a profound effect on their inactivation, the retroviruses such as HIV and Visna becoming undetectable after less than one hour of heat treatment.

摘要

相似文献

1
Characterisation and virus safety of alpha 1-proteinase inhibitor.
Eur Respir J Suppl. 1990 Mar;9:35s-38s.
2
Production of alpha 1-proteinase inhibitor (human).
Eur Respir J Suppl. 1990 Mar;9:16s-20s.
3
Purification of alpha 1 proteinase inhibitor from human plasma fraction IV-1 by ion exchange chromatography.通过离子交换色谱法从人血浆IV-1组分中纯化α1蛋白酶抑制剂。
Vox Sang. 1998;74(4):232-41.
4
Inactivation and clearance of viruses during the manufacture of high purity factor IX.高纯度凝血因子IX生产过程中病毒的灭活与清除
Biologicals. 2000 Sep;28(3):129-36. doi: 10.1006/biol.1999.0242.
5
Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.通过巴氏消毒法灭活人血浆衍生物中的HIV、HBV、HCV相关病毒及其他病毒。
Dev Biol Stand. 1993;81:169-76.
6
[Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].[对经过两种特定病毒灭活处理(FANDHI)的高纯度人凝血因子VIII浓缩物的病毒安全性评估]
Sangre (Barc). 1996 Apr;41(2):131-6.
7
Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.用于提高从人血浆制备的抗血友病因子VIII浓缩物病毒安全性的干热治疗工艺。
J Microbiol Biotechnol. 2008 May;18(5):997-1003.
8
Yield improvement for manufacture of alpha-proteinase inhibitor.提高α-蛋白酶抑制剂的生产产量。
Vox Sang. 2006 Nov;91(4):309-15. doi: 10.1111/j.1423-0410.2006.00841.x.
9
Preparation and properties of alpha 1-proteinase inhibitor concentrate from human plasma.人血浆α1-蛋白酶抑制剂浓缩物的制备及其性质
Vox Sang. 1985;48(6):333-42. doi: 10.1111/j.1423-0410.1985.tb00193.x.
10
Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.新型15纳米过滤液体免疫球蛋白产品Nanogam的病毒安全性
Vox Sang. 2006 Jan;90(1):21-32. doi: 10.1111/j.1423-0410.2005.00710.x.